DFDA

Entecavir

Treatment for Acute Hepatitis B

Typical Dosage: 0.5 mg orally once daily

Effectiveness
80%
Safety Score
68%
Clinical Trials
4
Participants
500

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
0.5 mg orally once daily
Time to Effect
2-4 weeks for initial viral response, clinical improvement varies
Treatment Duration
Variable, typically 6-12 months post HBsAg seroconversion or longer in severe cases
Evidence Quality
MODERATE
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$600
Monitoring:$750
Side Effect Mgmt:$100
Total Annual:$1,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$1,933
Cost per Remission
$2,231
Entecavir Outcomes

for Acute Hepatitis B

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Remission Rate
+65%
Common Side Effects
Headache
+6%
Fatigue
+4%
Dizziness
+3%
Nausea
+3%
Abdominal pain
+3%
Lactic acidosis (rare)
+0.1%
Renal impairment (less common than TDF)
+1%

Sources:

nih.gov
researchgate.net
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Entecavir in Acute Hepatitis B

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

NCT03920618RECRUITINGNA
View Study
150 participants
INTERVENTIONAL
Guangzhou, China
Started: Feb 21, 2019
Completed Clinical Trials
1 completed trial for Entecavir in Acute Hepatitis B

The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure

NCT01254994COMPLETEDPHASE2
View Study
108 participants
INTERVENTIONAL
Guangzhou, China
Started: Aug 1, 2007